ASH 2023 | Investigating bispecific antibodies in high-risk smoldering myeloma: the ImmunoPRISM platform study
Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, comments on early findings of Immuno-PRISM, a randomized Phase II platform study of bispecific antibodies in high-risk smoldering multiple myeloma (HR-SMM) (NCT05469893). This study compares teclistamab, a bispecific antibody approved for use in relapsed/refractory (R/R) multiple myeloma (MM), to a control arm of lenalidomide and dexamethasone. Of the 12 patients treated to date, all have responded to teclistamab treatment and have achieved measurable residual disease (MRD) negativity. The safety profile of the agent was found to be more favorable than when it is used in the R/R setting, with lower rates of cytokine release syndrome (CRS) and infections. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on an entity’s Board of Directors or advisory committees: BMS, Sanofi, GPCR Therapeutics, GSK, Takeda, Janssen; Research Funding: Takeda, Janssen; Honoraria: Janssen.
